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Molecular evolutionRepulsive guidance molecule c (RGMc; gene symbol: Hfe2) plays a critical role in iron metabolism.
Inactivating mutations cause juvenile hemochromatosis, a severe iron overload disorder. Understanding
mechanisms controlling RGMc biosynthesis has been hampered by minimal information about the RGMc
gene. Here we deﬁne the structure, examine the evolution, and establish mechanisms of regulation of the
mouse RGMc gene. RGMc is a 4-exon gene that undergoes alternative RNA splicing to yield 3 mRNAs with 5′
different untranslated regions. Gene transcription is induced during myoblast differentiation, producing all 3
mRNAs. We identify 3 critical promoter elements responsible for transcriptional activation in skeletal muscle,
comprising paired E-boxes, a putative Stat and/or Ets element, and a MEF2 site, and muscle transcription
factors myogenin and MEF2C stimulate RGMc promoter function in non-muscle cells. As these elements are
conserved in RGMc genes from multiple species, our results suggest that RGMc has been a muscle-enriched
gene throughout its evolutionary history.hromosome; BCA, bicinchoninic
ia; DMEM, Dulbecco's modiﬁed
nzimidazole; E, embryonic day;
ansformation-Speciﬁc; FBS, fetal
matosis; MADS, MCM1 (mini-
esponse factor; MCK, creatine
, myosin heavy chain (myh3);
ewborn calf serum; RACE, rapid
olecule; RLU, relative luciferase
ion; STAT, signal transducers and
sites; TSS, transcription start site;
and Molecular Biology, Oregon
m Jackson Park Road, Portland,
l rights reserved.© 2010 Elsevier Inc. All rights reserved.1. Introduction
Iron-related metabolic and hematologic disorders affect millions of
individuals worldwide. Iron plays a critical role in numerous cellular
processes ranging from oxygen exchange and energy metabolism [1] to
nucleic acid synthesis and DNA repair [2], yet toomuch or too little iron
can cause severe tissue and organ damage [3]. As a result, iron levels are
tightly regulated in humans and other mammalian species [4], with
primary control being exerted at the level of absorption from the small
intestine [4,5]. Hemojuvelin (HJV) or repulsive guidance molecule c
(RGMc; approved gene symbol: Hfe2) is a recently identiﬁed gene that
was initially linked to systemic iron metabolism by the discovery that
mutations in humans caused the rapidly progressive and severe ironoverload disorder, juvenile hemochromatosis (JH) [6,7]. This relation-
ship was strengthened when mice engineered to lack RGMc also
developed iron overload [8,9]. As RGMc/HJV appears to indirectly
regulate the expressionof hepcidin (Hamp) [10–12], a peptide hormone
made in the liver that negatively controls intestinal iron absorption in
the duodenum [5,13], it is thus a component of a homeostatic pathway
that regulates iron uptake [3,8–10,12].
RGMc was discovered not only as a gene mutated in JH [10], but
also was identiﬁed as a novel transcript expressed during skeletal
muscle differentiation [14], and as a member of a conserved three-
gene family that receives its name from the axonal guidance molecule
RGMa [15–18]. Unlike RGMa or RGMb, RGMc is not expressed in the
central nervous system, but rather is produced by striated muscle and
by hepatocytes in the liver [14,15,18]. During development RGMc
transcripts are expressed ﬁrst in the somites in both mice and
zebraﬁsh [14,17,19], and then later in skeletal muscle, as well as in the
embryonic heart and liver [9,14]. This unique pattern of RGMc
expression in striated myocytes and hepatocytes is maintained in the
adult (Fig. 1A). To date, the responsible molecular mechanisms for
tissue-speciﬁc gene expression have not been elucidated, and very
little is known about RGMc gene regulation in any species, as no
promoter has been characterized. Here we deﬁne the structure of the
mouse RGMc gene and identify the DNA elements responsible for its
high-level gene transcription in skeletal muscle. Further analysis
reveals that these cis-acting muscle-specifying DNA elements are
highly conserved in RGMc genes from multiple mammalian species,
supporting the hypothesis that RGMc has been a muscle-enriched
gene throughout its evolutionary history.
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Fig. 1. Establishing mouse RGMc gene structure. A. RGMc mRNA is expressed in striated
muscle and in the liver. Results of RT-PCR experiments for RGMc, albumin, skeletalmuscle
myosin heavy chain polypeptide 3 (MHC), and S17 mRNAs using RNA from tissues (Sk,
skeletal muscle (gastrocnemius); Li, liver; K, kidney; Ht, heart; Lu, lung; St, stomach; Br,
brain) of adult male (left) and female (right) mice. B. Mapping the 5′ end of the mouse
RGMc gene by 5′ RACE usingmouse skeletalmuscle RNA. The number of clones is graphed
on the y-axis above the corresponding location of the 5′ residue on the x-axis. The putative
transcription start site is denoted as +1 (arrowhead), with exon 1 in upper case letters. A
potential TATA box is labeled, and primers II - IV used in (C) are indicated below the
sequence. C. Mapping the 5′ end of the mouse RGMc gene by RT-PCR with cDNA from
mouse skeletal muscle RNA and overlapping PCR primers located in different parts of
RGMc exon 1, as seen on the gene map to the left (see Supplemental Table 1 for DNA
sequences of primers). Exons 1 and 2 are depicted as boxes,with the 5′UTR in gray and the
protein coding region inblack, and introns andﬂankingDNAashorizontal lines. Results are
seen to the right, and molecular weight markers are indicated (see Supplemental Fig. 1A
for results with heart and liver RNA). In addition to mapping the 5′ end of exon 1, the
results also show that alternative RNA splicing occurs between exons 1 and 2. D. DNA
sequenceof the junctionbetween intron1andexon2of themouseRGMcgene. Exon2 is in
upper case letters; the locations of alternative RNA splicing are noted by chevrons, with the
–AG splice-acceptor residues underlined. E. Organization of the mouse RGMc gene and
mRNAs. The gene contains 4 exons (boxes) and three introns (thin lines). The transcription
start site is denoted as a bent arrow, and the polyadenylation site as a vertical arrow. The
threeRGMcmRNAsare diagramedbelow, andresult fromuseof alternative splice acceptor
sites at the 5′ end of exon 2.
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2.1. Deﬁning RGMc gene structure
Analyses of genomic databases suggest that RGMc is a 4-exon gene
in mice, humans, and several other species [20], but the 5′ end of exon1 has not been established in any species, and the promoter has not
been characterized. We thus mapped the transcription start site for
mouse RGMc as a means to ﬁrst identify and then functionally dissect
the promoter. RGMc mRNA is expressed in adult male and female
mouse skeletal and cardiac muscle and in the liver with no apparent
gender differences in transcript abundance, at least in the C57Bl6
strain (Fig. 1A). By 5′ RACE we mapped the RGMc transcription start
site (TSS) in skeletal muscle, and found that the 5′ end of 14/15
independent cDNA clones clustered within a 5-nucleotide region that
was located ~25 nucleotides 3′ to a putative TATA box [21] in genomic
DNA (Fig. 1B). We obtained similar results by RT-PCR with over-
lapping exon 1-speciﬁc primers and mouse muscle RNA (Fig. 1C),
which validated the same TSS with RNA from mouse heart and liver
(Supplemental Fig. 1).
The RT-PCR experiments designed tomap the 5′ end of RGMc exon
1 used a common primer located in exon 2 (Fig. 1C), and results
consistently yielded 3 distinct cDNAs that differed in length by 18 to
77 nucleotides (Fig. 1C and Supplemental Fig. 1). By DNA sequencing,
all three classes of cDNAs contained identical parts of RGMc exon 1,
but differed in the extent of exon 2 (all sequences matched mouse
RGMc genomic DNA, Fig. 1D and Supplemental Fig. 1). We interpret
these results to indicate that the mouse RGMc gene undergoes
alternative RNA splicing to generate transcripts with varying lengths
of exon 2, a hypothesis supported by evidence for splice acceptor sites
at each of the three putative junctions between intron 1 and exon 2
(AG nucleotides underlined in Fig. 1D). Additional support comes
from an expressed mouse sequence tag in GenBank (AI196626),
which matches the intermediate-sized version of exon 2. A similar
intermediate-sized exon 2 has been identiﬁed for human RGMc (EST
numbers: DA762328 and DA764726). Also, comparative analyses of
10 mammalian species reveals sufﬁciently similar genomic DNA
sequences to suggest that alternative RNA splicing is a common
feature of many RGMc genes (Supplemental Fig. 1). Taken together,
our results show that mouse RGMc is a 4-exon gene with a discrete
TSS in exon 1 and alternative RNA splicing involving exon 2 that leads
to three distinct transcripts that vary in the length of the 5′
untranslated region (Fig. 1E).
2.2. RGMc gene transcription is induced during skeletal muscle
differentiation
We next examined RGMc gene expression during skeletal muscle
differentiation, using the C2 myoblast line as a model [22–24]
(Fig. 2A). RGMc mRNA was detected within 12 hr after onset of C2
cell differentiation, and its abundance increased progressively during
the subsequent 60 hr in a pattern similar to myogenin, a critical
transcription factor that is expressed early in muscle differentiation
[25,26] (Fig. 2B). Accumulation of RGMc mRNA in differentiating C2
myoblasts appeared to be a secondary to induction of RGMc gene
transcription, as measured by stimulation of nascent nuclear RGMc
RNA beginning at ~8 hr after addition of DM, a pattern that was
temporally similar to myogenin gene (MYOG) activation (Fig. 2C). We
also examined RGMc mRNA stability in myoblasts after 48 hr of
differentiation [27], and found that RGMc is a moderately long-lived
mRNA, with a half-life of ~5.2 hrs, more than twice that of myogenin,
and nearly four times as long as MyoD (Fig. 2D). Taken together,
results in Fig. 2 demonstrate that induction of RGMc gene transcrip-
tion is a critical regulatory step responsible for accumulation of RGMc
mRNA in differentiating muscle cells.
2.3. Analysis of RGMc promoter function in muscle differentiation
To investigate RGMc promoter function in myoblasts, we ﬁrst
showed that a genomic fragment containing ~4.1 kb of 5′ ﬂanking
DNA plus 118 nt of exon 1 could stimulate luciferase reporter activity
in differentiating C2 myoblasts and in 10T½ mesenchymal stem cells
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Fig. 2. RGMc gene transcription is induced during skeletal muscle differentiation.
A. Myotube formation occurs during C2 myoblast differentiation, as illustrated by phase
contrast microscopy (200X magniﬁcation) at conﬂuent cell density (0 hr) and after
incubation in DM for 48 hr. Scale bar is 250 μm. B. Time course of gene expression for
RGMc, myogenin, MEF2C, MyoD, myosin heavy chain (MHC), muscle creatine kinase
(MCK), and S17 during C2myoblast differentiation measured by RT-PCR. C. Time course
of RGMc, myogenin, and S17 gene transcription during C2 myoblast differentiation, as
measured by accumulation of nascent nuclear transcripts. Gene maps are to the right,
and show approximate locations of intron-exon primer pairs (see Supplemental Table 1
for DNA sequences of primers). Exons appear as black boxes (exon sizes are not to
scale). D.Measurement of mRNA half-life for RGMc, myogenin, MyoD, MEF2C, and S17
mRNAs in differentiating C2 myoblasts. The T½ for each mRNA is listed to the right of
a representative experiment (the 95% conﬁdence interval is in parentheses). See
‘Materials and Methods’ for details.
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recombinant adenovirus [28]. In each cell line, RGMc promoter activity
was enhanced by ~35-fold after induction of muscle differentiation to
levels ~10% of a myogenin promoter - reporter plasmid, whose activity
also was stimulated during differentiation (Fig. 3A). In contrast, neither
RGMc nor myogenin were activated in 10T½ cells in the absence
of MyoD (data not shown), providing further support for the idea
that RGMc gene transcription is induced during skeletal muscle
differentiation.
To identify the DNA elements responsible for the transcriptional
activity of RGMc during muscle differentiation we analyzed a series of
5′ promoter deletions. Three major regions were identiﬁed based ondeclines in reporter gene activity when each segment was eliminated:
nucleotides -620 to -506, -136 to -110, and -110 to -88 (Fig. 3B and
Supplemental Fig. 2).
We looked for additional transcriptional control regions that
might be active in muscle differentiation, and evaluated 3 regions that
spanned the entire body of themouse RGMc gene and 3′ ﬂanking DNA
(Fig. 4A). As none of these DNA fragments altered induction of RGMc
promoter activity during muscle differentiation (Fig. 4B), the results
indicate no other muscle transcriptional enhancers (or repressors) are
located outside of the RGMc proximal promoter.
2.4. Identifying proximal promoter elements responsible for RGMc
transcriptional activity during muscle differentiation
We introduced inactivating nucleotide substitutions into DNA
sequences potentially responsible for RGMc promoter activity during
muscle differentiation (Fig. 3). Mutation of two E-boxes (putative
binding sites for myogenic basic helix-loop-helix (bHLH) transcrip-
tion factors, including MyoD and myogenin, with the consensus
sequence, CANNTG) in the segment from -620 to -506 (α-element,
Fig. 5) resulted in a 50% decrease in promoter activity in MyoD-
expressing 10T½ cells, and a 25% decline in C2 myoblasts (Fig. 5).
Disruption of a putative myocyte enhancer factor 2 (MEF2) sequence
from -110 to -88 (γ, Fig. 5) caused a 50% reduction in MyoD 10T½
cells, and a ~75% decrease in C2 myoblasts (Fig. 5). By contrast,
elimination of a potential Stat binding site (TTCN3GAA [29–31]) and/or
Ets element (GGA(A/T) [32–34]) from -136 to -110 (β, Fig. 5), was less
effective, and led to only a ~25% decline in promoter activity in MyoD
10T½ cells, and had no effect in C2myoblasts, althoughwhen combined
with mutation of the γ region, RGMc promoter activity was decreased
by ~75 - 90% (Fig. 5A). Mutation of all three elements reduced reporter
gene expression to basal levels, results thatwe interpret to demonstrate
that together these three proximal promoter sites are responsible
for RGMc transcriptional activity during skeletal muscle differentiation.
As depicted in Fig. 5B, both of the E-boxes and the MEF2 site are highly
conserved in putative RGMc gene promoters from 9 mammalian
species, while the postulated Stat/Ets composite element is less
conserved.
To directly test the role of MEF2 proteins and myogenic bHLH
transcription factors in regulating RGMc promoter function, we
performed co-transfection experiments in non-muscle 10T½ cells.
Constitutively active MEF2C (MEF2C-VP16) was able to stimulate
RGMc promoter activity by ~10-fold over an empty vector control, but
had little effect on an RGMc promoter-reporter gene with an
inactivating mutation in the MEF2 site (Fig. 6A). Similarly, myogenin
was able to increase RGMc promoter activity by N20-fold, but this was
reduced by only ~50% for the α-element mutant (Fig. 6B), possibly
because another conserved E-box is found in the RGMc proximal
promoter at -53 to -48 (Fig. 5B). In contrast to these results,
constitutively active Stat5b was not able to stimulate RGMc promoter
activity (data not shown).
2.5. Little activity of the RGMc promoter in liver cell lines
RGMc may be one of the only genes expressed exclusively in
striated muscle and in hepatocytes. To investigate RGMc promoter
function in liver cells, we performed a series of transfection
experiments with mouse RGMc promoter-luciferase fusion genes
into human Hep3B liver cancer cells, which have been reported to
produce RGMcmRNA [12], and intomouse AML-12 hepatocytes. None
of the 5 promoter deletions tested were active, as luciferase values
were b10% of what was measured with a thymidine kinase promoter-
reporter plasmid, and were b1% of the activity seen with mouse Igf2
promoter 3 (Fig. 7). Similarly negative results were seen when the
region from+2812 to +7540 of the mouse RGMc gene was added to
the promoter-reporter plasmid (Fig. 7), or when the RGMc promoter-
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Fig. 3.Mapping the regions of the RGMc promoter that are induced during muscle differentiation. Results of luciferase assays in differentiating Ad:MyoD-10T½ cells (left panels) and
C2myoblasts (right panels) that were transiently transfected with reporter genes containing (A) theminimal thymidine kinase (TK) promoter, themousemyogenin promoter, or the
mouse RGMc promoter (coordinates -4204 to +118), and (B) reporter genes containing a series of 5′ truncations of the mouse RGMc promoter. Cells were incubated in DM for 0
(white bars), or 24 or 48 hr (gray bars). The graphs summarize results of 3 - 5 independent experiments (mean±S.E.), each performed in duplicate (* - pb0.05, ** - pb0.005).
Myogenin promoter values at t 0 have been set to 100 in each graph (average measurements at t 0 were 7.8×104 (Ad-MyoD-10T½ cells) or 7.3×103 (C2 cells) light units/μg total
protein/sec).
345C.J. Severyn, P. Rotwein / Genomics 96 (2010) 342–351luciferase fusion genes were transfected into human HepG2 hepato-
carcinoma cells (Supplemental Fig. 3). Based on these results, it
appears that the regulatory domains responsible for RGMc transcrip-
tional activity in liver cells do not map to the promoter or the body31 4
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Fig. 4. Analyzing the RGMc gene for potential transcriptional enhancers. A. Map of
mouse RGMc gene showing regions that were fused downstream of ﬁreﬂy luciferase
(Luc) and the RGMc promoter (coordinates -620 to +118) to test for enhancer activity
in differentiating Ad-MyoD-10T½ cells. B. Graphs depict results of luciferase assays after
incubation inDMfor0 (whitebars) or24 hr (graybars) (mean±S.E. of 3 experiments, each
performed induplicate; values for the RGMcpromoter at 24 hrwere set to 100 (* - pb0.01,
** - pb0.001, vs. t 0)).of the gene, or that the transcription factors necessary for RGMc
expression are not produced in Hep3B, AML-12, or HepG2 cells.
2.6. Evolutionary conservation of the RGMc gene promoter
An assumption in genomics is that evolutionarily well-conserved
regions of the genome are more likely to be functionally important
than are segments that have diverged. Although counter examples
exist where ultra-conserved DNA when deleted in transgenic mice
showed little effect on phenotype [35], there are numerous individual
cases where evolutionary conservation has provided critical insight
into gene function [36,37]. The mouse RGMc promoter elements
identiﬁed here as being responsible for RGMc gene regulation in
muscle are highly conserved among mammals, although are less so in
zebraﬁsh (Fig. 8B), and the 750 bp of the proximal promoter 5′ to the
TSS is nearly as conserved in mammals as RGMc exon 1, although it is
less than the coding exons (Figs. 8A and C). Of note, even though the
putative RGMc promoter is more divergent in zebraﬁsh, islands of
conserved sequences for potential muscle-speciﬁc transcriptional
elements are found adjacent to the putative TSS (see Supplemental
Fig. 4 and discussion below), which is consistent with the hypothesis
that RGMc expression in muscle is evolutionarily ancient.
3. Discussion
Experiments presented in this manuscript delineate the topogra-
phy of the mouse RGMc gene and deﬁne mechanisms of RGMc gene
regulation. Key ﬁndings include the demonstration of alternative RNA
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Fig. 5. Characterizing promoter elements that control RGMc gene transcription duringmuscle differentiation. A. Results are depicted of luciferase assays in differentiating Ad:MyoD-10T½
cells (left panel) and C2myoblasts (right panel) transiently transfectedwith reporter genes containing substitutionmutations of themouse RGMc promoter (illustrated on themaps to the
far left; details are in (B) and ‘Materials andMethods’). Cellswere incubated inDMfor 0 (white bars), or 24or48 hr (graybars) before analysis. The graphs depict results of 3 - 10 independent
experiments (mean±S.E.), each performed in duplicate (* - pb0.05, ** - pb0.001, vs. t 0). B . Comparative mapping of RGMc promoter elements from different species. DNA sequence
alignment of part of the proximal RGMc promoter from9mammalian species. Highlighted regions include paired E-boxes at -588 to -583 and -514 to -509 (α-site), theβ-site from -120 to
-110, and the γ site, a putative MEF2 element, from -98 to -85. Another E-box also is indicated at -53 to -48. Mouse exon 1 is in upper case and bold letters.
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347C.J. Severyn, P. Rotwein / Genomics 96 (2010) 342–351splicingbetweenexons1 and2,which leads to expression inmuscle and
liver of three distinct RGMc transcripts that vary in the length of the 5′
UTR, and the identiﬁcation and characterization of DNA elements in the
proximal RGMc promoter responsible for RGMc gene transcription in
skeletalmuscle. Additionally, we show that a 4 kb segment of the RGMc
promoter is insufﬁcient to direct transcription in three liver cell lines.
Comparative analysis of RGMc genes from 10 mammalian species
further supports the hypothesis that both differential RNA processing
and at least two of the three the muscle-speciﬁc promoter elements
have been evolutionarily conserved.
Many genes undergo alternative RNA splicing [38–41], which can
lead to transcripts encoding different protein species [38,42] or
containing distinct regulatory properties, such as differential stability
or translatability [43]. The precise mechanisms that control alterna-
tive splicing are complex, and full understanding of how splice-site
selection is determined remains incomplete [39]. For RGMc the threeRGMc
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AML-12 hepatocytes (right) transiently transfected with reporter genes containing different
for 24 hr before analysis (mean of 2 independent experiments in duplicate for RGMc const
Values for TK-luciferase were set to 100 relative luciferase activity units (average measurememRNAs characterized here vary in the length of the 5′UTR, and appear
to be expressed at fairly equivalent levels in muscle and liver. Further
studies will be needed to determine if there are unique functional
properties for each transcript.
Like several other genes expressed in skeletal muscle, RGMc gene
transcription is controlled by a combinatorial interplay of muscle-
restricted and more broadly expressed transcription factors, including
members of the myogenic bHLH family, which includes Myf-5,
MyoD, myogenin, and MRF4 [44–46], and the MEF2-family, MEF2A -
D [47,48]. MEF2C has been shown to be directly activated by and to
cooperate functionally with myogenic bHLH proteins during muscle
differentiation in vitro [49], and during skeletal muscle development in
vivo [50]. Our results demonstrate that a set of paired E-boxes (α-
element) and a MEF2 site (γ-element) are critical for RGMc promoter
activity in muscle cells, and suggest that myogenin and MEF2C may be
key transcription factors acting at these sites. We also have identiﬁed a
third region in the proximal RGMc promoter, termed the β-element,
that also is necessary for full transcriptional activity in differentiating
muscle cells, but have not yet deﬁned the responsible transcription
factors. Leading candidates includemembers of the Stat and Ets families,
although our preliminary studies rule out Stat5b. Both Stat3 and several
Ets factors will need to be tested, as each has been shown to positively
regulate gene expression during muscle differentiation [51–53].
RGMc is also expressed in cardiacmuscle and in hepatocytes (Fig. 1A,
and [9,14,15,17–19]). To our knowledge there are no other genes that
exhibit this pattern of gene expression, placing RGMc in a unique
position to provide insights into distinct tissue-speciﬁc transcriptional
regulatory mechanisms. Unfortunately our initial studies did not reveal
any information on transcriptional control in the liver, as the RGMc
promoterwasminimally functional in the three hepatic cell lines tested.
Of note, RGMc mRNA is not produced in the liver of mice lacking the
liver-enriched transcription factor HNF4α [54], and ChIP-seq studies
with human liver chromatin have identiﬁed a peak of HNF4α binding
near the human RGMc promoter (personal communication from M. D.
Wilson of the Department of Oncology, University of Cambridge, UK;
also see ref [37]). Clearly, future studies should focus on deﬁning
mechanisms responsible for RGMcgeneactivity inbothhepatocytes and
cardiac myocytes.
The results presented in this manuscript represent the ﬁrst analysis
of promoter function for anymember of the RGM family. As both RGMa
and RGMb have completely different proﬁles of gene expression than
RGMc, being produced in distinct parts of the central nervous system,
and not in muscle or liver [15–18,55,56], it is likely that the critical
transcriptional control elements will be different. However, compara-
tive genomic analysis of RgmaandRgmbgenes indicates thepresence of4
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Fig. 8. Evolutionary conservation of the RGMc gene and promoter. A. Graphs depicting nucleotide conservation between mouse RGMc and either rhesus macaque, human, or dog
RGMc/HJV. The horizontal length of each conserved block on the x-axis corresponds to the length of the alignment, and the y-axis depicts the percent identity over a 100 bp sliding
window for each block between mouse and the corresponding species listed (results derived from tools in Ref. [66]). Regions with N70% identity over 100 bp are shown in red and
highlighted above the alignment, with repetitive elements in green within these blocks. Regions below 50% conservation are not pictured. Below the graphs is a diagram of mouse
RGMc (non-coding regions in yellow, protein coding sequences in blue). B. RGMc promoter conservation between mouse and rhesus macaque, human, dog, or zebraﬁsh presented in
250 nt increments from 1 to 1000 nt 5′ to the TSS. Alignments were created using the EMBOSS Needleman-Wunsch (GLOBAL) alignment algorithm utilizing the EDNAFULL
substitution matrix from the European Bioinformatics institute (EBI) with a Gap Penalty of 10.0 and Extension Penalty of 0.5. NCBI reference sequences includemouse,NT_039240.7;
rhesus macaque, NW_001108926; human, NT_167185.1; dog, NW_876264.1; zebraﬁsh, NW_001877680.2. C. Characteristics of the RGMc gene in mouse, rhesus macaque, human,
dog, and zebraﬁsh. Exons are numbered with lengths in bp (and introns in kb), with non-coding regions in yellow and coding sequences in blue as in (A), and % identity in relation to
mouse RGMc noted in parentheses. Exon 2 splice variants are not shown for simplicity (for additional details see Fig. 1). Only the smallest exon 2 is compared. There are no full-length
cDNAs in public databases for rhesus macaque or dog RGMc, and the lengths of exon 1 have been derived based on similarity with mouse and human exon 1. Similarly, there is no
information available for the 3′ UTR of dog RGMcmRNA that would correspond to the non-coding part of exon 4 (listed as NA in the ﬁgure). There is a 138 nt repetitive DNA element
in dog RGMc exon 3, which has been eliminated to allow comparisons with the other species (the actual length of dog exon 3 is 703 nt). The zebraﬁsh RGMc gene contains 5 exons.
Exons 1 and 2 are listed together as 65+58 nt (exon 1 is 65 nt, exon 2 is 58 nt, with a 2.0 kb intron separating them).
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promoters (data not shown), which could be regulated by neuronal
speciﬁc bHLH proteins such as N-twist [57] in conjunction with MEF2
family members. Future studies will be needed to deﬁne the speciﬁc
mechanisms of regulation of Rgma and Rgmb gene transcription.
RGMc mRNA has been detected in skeletal muscle from several
vertebrates ranging from mice to zebraﬁsh [14,17,19,20]. While
mouse and zebraﬁsh RGMc promoters are not well-conserved across
the entire region upstream of the ﬁrst known exon (Figs. 8B and C), a
bio-informatics analysis reveals the presence of several E-boxes, MEF2
sites, and Ets/Stat elements in the putative zebraﬁsh promoter
(Supplemental Fig. 4), suggesting that similar transcriptional mechan-
isms to those identiﬁed for the mouse RGMc gene in skeletal muscle
may be active in zebraﬁsh muscle. In addition, a single RGM gene has
been identiﬁed in the urochordate, Ciona intestinalis (sea squirt),
based on genomic data [20,58]. The RGM gene in Ciona appears to
contain 4 exons, and numerous MEF2, E-box, and Stat/Ets-sites
surround the putative promoter (Supplemental Fig. 4), although it is
not knownwhether Ciona RGM is expressed inmuscle. Understanding
the mechanisms controlling expression of the three RGM genes in
vertebrates and the single RGM in a model organism like Ciona
will help deﬁne the evolutionary history of the entire RGM family
and discern how each member acquired its distinct tissue-speciﬁc
regulatory modules.4. Materials and Methods
4.1. Materials
Restriction enzymes, buffers, ligases, and polymerases were pur-
chased from New England Biolabs (Beverly, MA), BD Biosciences
(Clontech, Mountain View, CA), and Fermentas (Hanover, MD). The
BCA protein assay kit was from Pierce (Thermo Scientiﬁc Life Sciences,
Rockford, IL), and theQuikChangeXL site-directedmutagenesis kit from
Stratagene (La Jolla, CA). TransIT LT-1 was from Mirus Corp (Madison,
WI). Dulbecco's modiﬁed Eagle's medium (DMEM), Superscript III ﬁrst-
strand synthesis kit, Trizol, and horse serum were from Life Technol-
ogies (Carlsbad, CA). Fetal bovine serum (FBS) and newborn calf serum
(NCS) were from Hyclone (Logan, UT). Luciferase assay reagent was
purchased from Promega (Madison, WI). DRB (5,6-dichloro-1-β-D-
ribofuranosylbenzimidazole) was from Sigma (St. Louis, MO), and DNA
puriﬁcation reagents fromQiagen (Valencia, CA). Oligonucleotideswere
synthesized at the OHSU DNA Services Core. All other chemicals were
reagent grade and were purchased from commercial suppliers.
4.2. Construction of RGMc promoter-reporter plasmids
MouseRGMcgenomicDNAwas isolated fromBACcloneRP24-136I19
(Children's Hospital Oakland Research Institute BACPAC resource
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characterized in this manuscript match what is present in mouse
genome databases [59] except for a 33-bp region of intron 2, which is
not present in the BAC DNA. DNA fragments generated by restriction
enzyme digestion or PCR were puriﬁed after preparative agarose gel
electrophoresis by ion-exchange chromatography (Qiaexx II gel extrac-
tion kit, Qiagen), and sub-cloned into the pGL3-basic ﬁreﬂy luciferase
vector (Promega) by standardmethods.Mutations in theRGMcpromoter
were introduced by site-directed mutagenesis with the following
oligonucleotide primers (top strand is shown, mutations are in lower
case): E-box at -588 to -583: 5′-GGTGGAGAGAGAGTAGAgctagcCAGA-
GATCTGATCTGGGC-3′; E-box at -514 to -509: 5′-GCTCTCGGATTTCTCGG-
GAgggcccGACCTTTCAGCTTCTG-3′; β-site at -119 to -111: 5′-GCTCCCACA
CCCCACTGCCACCAACGcgtCTGcccTTTTGGACCTAG-3′; MEF2 site at -98
to -84: 5′-CCTGGAATTTTGGACCTAGtggccaTTAgAAtTcTCAACTCAG-
TAGGC ACCTCCCTCCTCC-3′. All DNA modiﬁcations were conﬁrmed by
sequencing.
4.3. Cell culture
Cells were incubated at 37 °C in humidiﬁed air with 5% CO2. C2
myoblasts (passages 4 to 10) were grown on gelatin-coated tissue
culture dishes in DMEM with 10% heat-inactivated FBS and 10% NCS.
At conﬂuent density cells were washed and low-serum differentiation
medium was added (DM=DMEM with 2% horse serum). Cell images
were captured by phase contrast microscopy using a Nikon Eclipse
T300 microscope with an attached Roper Scientiﬁc Cool Snap FX CCD
camera. C3H10T½ mouse embryonic ﬁbroblasts (#CCL-226, ATCC,
Manassas, VA) were maintained between passages 12 and 18, and
incubated on gelatin-coated dishes in DMEM plus 10% FBS. They were
converted to myoblasts by infection with a recombinant adenovirus
for mouse MyoD [60], followed by incubation in DM as above. Mouse
AML12 cells (ATTC #CRL-2254) were incubated in a 1:1 mixture of
DMEM and Ham's F12medium supplementedwith ITS (Final concentra-
tions: 10 μg/ml insulin (I), 5.5 μg/ml transferrin (T), 6.7 ng/ml selenium
(S)), 0.1 μM dexamethasone, and 10% FBS. Human hepatoma cell lines
HepG2 (ATTC #HB-8065) andHep3B (ATTC #HB-8064)were cultured in
Eagle's MEM plus 10% FBS.
4.4. Recombinant adenoviruses
Recombinant adenoviruses forMyoD (Ad-MyoD) andβ-galactosidase
(Ad-β-gal) were prepared as described [60].
4.5. Analysis of gene transcription by promoter-reporter gene assays
C2 and 10T½ cells on gelatin-coated 12-well plates were transfected
with individual RGMc promoter-reporter plasmids or with controls
[(thymidine-kinase (TK) - Luc [61], mouse myogenin - Luc [28], mouse
IGF-II promoter 3 - Luc [62], 4xE-box TK - Luc [28]] at 50% or 25% of
conﬂuent density, respectively (0.7 μg of plasmid DNA per well for C2
cells, 0.4 μg for 10T½cells). C2 cell extractswere harvested either one day
later (undifferentiated), or after DM was added for an additional 48 hr
(differentiated). For 10T½ cells, one day after transfection cells were
infected with Ad-MyoD or Ad-β-gal, and extracts were collected
following another day in growth medium (undifferentiated), or after
DM was added for 24 hr (differentiated). Cell extracts from individual
experiments were stored at -80 °C, and were assayed together for
luciferase activity, as described [28], and results were normalized to
cellular protein concentrations. At least 3 experiments were performed
for each promoter - reporter plasmid using duplicate transfections per
experiment. To assess effects of myogenin or MEF2 on RGMc promoter
activity, co-transfection experiments were performed in 10T½ cells with
selected RGMc promoter - reporter genes, and expression plasmids for
mouse myogenin (myogenin-IRES-EGFP or EGFP [28]), or constitutivelyactive MEF2C (MEF2C-VP16 - from J. Molkentin [47,63]) in pcDNA3 or
empty vector.
4.6. Animal studies
Male and female C57Bl6 mice were housed at the OHSU Animal
Care Facility on a 12 hr light/dark schedule with free access to food
andwater, and received care according to National Institutes of Health
guidelines. At 3 months of age, mice were euthanized by cervical
dislocation and tissues were harvested, ﬂash-frozen in liquid nitrogen,
and pulverized prior to RNA isolation. Animal studies were approved
by the OHSU Animal Care and Use Committee.
4.7. RNA isolation and analysis
Total cellular RNA was isolated from cells and tissues using Trizol,
followed by sodium acetate-ethanol precipitation and suspension in
RNAse-free de-ionized water. Nuclear RNA was isolated from cells as
described [62]. RNA concentrations were determined spectrophoto-
metrically at 260 nm, and quality assessed by agarose gel electropho-
resis. RNA (5 μg) was reverse transcribed in a ﬁnal volume of 20 μl,
with either oligo-dT primers (for total RNA) or random hexamers (for
nuclear RNA), and PCR was performed with 0.1 μl of cDNA and the
primers listed in Supplemental Table 1. The linear range of product
ampliﬁcationwas established in pilot studies for each primer pair, and
the cycle number that reﬂected the approximate midpoint was used
in ﬁnal experiments. This varied from 18 - 30 cycles for total RNA and
from 25 - 30 cycles for nuclear RNA. Results were visualized after
electrophoresis through 1.0 - 1.8% agarose or 10% PAGE gels.
4.8. RNA half-life
Conﬂuent C2 cells were incubated in DM for 48 hr, washed, and DRB
[75 μM] was added in DM for 0.5 to 12 hr. Total cellular RNA was
isolated, and used in RT-PCR experiments, as above. Half-life was
determined by averaging results of two independent experiments using
non-linear regression ﬁt to a one-phase decay equation, Y=Y0 • e-kX.
4.9. Mapping the 5′ end of the mouse RGMc gene
The 5′ RACE method was employed with mouse skeletal muscle
RNA. First strand cDNA was prepared using speciﬁc primers
complementary to portions of mouse RGMc exons 2 and 4 (Sup-
plemental Table 1). Subsequent steps were as described [64,65], with
primers for second strand cDNA synthesis from RGMc exon 1
(Supplemental Table 1), and for PCR from RGMc exon 1 and a poly
T adaptor (Supplemental Table 1). Gel-puriﬁed PCR products were
cloned into the pGEM-T Easy vector (Promega), and the DNA was
sequenced. A total of 15 independent clones were analyzed. A nested
RT-PCR-based method also was used to map the 5′ extent of RGMc
exon 1 from mouse muscle, liver, and heart RNA. Primers are listed
in Supplemental Table 1. A total of 83 independent clones were
characterized by restriction enzymemapping and/or DNA sequencing.
4.10. Data Analysis
Results were graphed and analyzed using Prism (GraphPad
Software, San Diego, CA) or Excel (Microsoft, Redmond, WA). All
differences were assessed using Student's t-test with pb0.05 as a cut-
off for signiﬁcance.
4.11. Computational Analysis
We manually compared putative RGMc promoter sequences from
other species with mouse RGMc, and used information from the UCSC
Genome Browser [59] and the LLNL-ECR Browser [66] to perform
350 C.J. Severyn, P. Rotwein / Genomics 96 (2010) 342–351alignments of RGMc exons and introns. Additional information on
genomic alignments may be found in Ref. [20]. Blocks of DNA
sequence were compared using EBI “Align” algorithm written by Alan
Bleasby (see references [67,68]). Transcription factor sites were
analyzed using Dcode [69], rVista 2.0 [70], the TRANSFAC database
[71], and JASPAR [72], and were individually conﬁrmed with original
primary references, as cited within this manuscript.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2010.09.001.
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